Clinical Trial Update: BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating cemiplimab for advanced cutaneous T-cell lymphoma (Mycosis fungoides) has been withdrawn (NCT05538988).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Mycosis Fungoides | Phase 1, Phase 2 | Status: WITHDRAWN